



## **Press Release**

Uppsala, October 9, 2000

### **Gyros AB appoints Vice President Sales Worldwide**

Gyros AB announced today the appointment of Richard Millett, as Vice President Sales Worldwide. Mr Millett previously held positions as Managing Director of LJL Biosystems Ltd and Vice President of their European Operations.

Gyros AB announced today the appointment of Richard Millett as Vice President Sales. Mr. Millett will establish the first Gyros AB subsidiary in the UK and further develop the company's international sales operation.

'We have received such a high level of interest in our proprietary technology from our contacts with major pharmaceutical and diagnostic organizations that we believe the time is right to begin developing our domestic and international marketing efforts', said Per Sjöberg, Vice President Commercial Operations at Gyros AB in Uppsala, Sweden.

'We are extremely pleased that Mr. Millett will join us', said Mr. Sjöberg, 'He has been highly successful in building up a number of businesses in the pharmaceutical and biotechnology market, beginning with Biacore AB and, more recently, as a regional head at LJL Biosystems. His experience in working globally at senior positions in rapidly growing companies will greatly strengthen the further development of our marketing and sales organization.

#### **About Gyros AB**

Gyros AB offers the pharmaceutical, biotechnology and diagnostic companies access to a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into client-specific CDs. Thousands of analyses can be performed in parallel on each disposable microlaboratory. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. The company was founded in 2000 and has its offices based in the Science Park in Uppsala, Sweden.

**For further information, visit [www.gyrosmicro.com](http://www.gyrosmicro.com) or contact:**

Maris Hartmanis, President and CEO, Gyros AB  
Tel: +46 (0)18 566 330  
Mobile: +46 (0)70 562 8617

Email: [maris.hartmanis@gyrosmicro.com](mailto:maris.hartmanis@gyrosmicro.com)

Per Sjöberg, Vice President Commercial Operations, Gyros AB

Tel: +46 (0)18 566 318

Mobile: +46 (0)70 5444799

Email: [per.sjoberg@gyrosmicro.com](mailto:per.sjoberg@gyrosmicro.com)

Media information (financial)

Maris Hartmanis, President and CEO, Gyros AB

Tel: +46 (0)18 566 330

Mobile: +46 (0)70 562 8617

Email: [maris.hartmanis@gyrosmicro.com](mailto:maris.hartmanis@gyrosmicro.com)

Media information (trade):

Sue Cresswell, Marketing Communications

Tel: +46 (0)8 54472620

Mobile: +46 (0)705 519520

Email: [sue.cresswell@gyrosmicro.com](mailto:sue.cresswell@gyrosmicro.com)

-----  
Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.  
-----